Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.79 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.70 |
| ▸ | MEN1 | O00255 | 4/20 | 0.70 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.65 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7756182 | 1.00 | SMN1; SMN2 (0.79) | SMN1; SMN2KDM4EKMT2AMEN1L3MBTL1 | |
| SCHEMBL29040265 | 0.94 | SMN1; SMN2 (0.82) | SMN1; SMN2KDM4EKMT2AMEN1L3MBTL1 | |
| SCHEMBL11623286 | 0.94 | SMN1; SMN2 (0.82) | SMN1; SMN2KDM4EKMT2AMEN1L3MBTL1 | |
| SCHEMBL6783522 | 0.89 | SMN1; SMN2 (0.75) | SMN1; SMN2KDM4EKMT2AMEN1L3MBTL1 | |
| SCHEMBL11623002 | 0.88 | SMN1; SMN2 (0.73) | SMN1; SMN2KDM4EKMT2AMEN1L3MBTL1 | |
| SCHEMBL1298199 | 0.88 | SMN1; SMN2 (1.00) | SMN1; SMN2KDM4EKMT2AMEN1L3MBTL1 | |
| SCHEMBL13969980 | 0.85 | KMT2A (0.69) | SMN1; SMN2KDM4EKMT2AMEN1L3MBTL1 | |
| SCHEMBL12530589 | 0.83 | KMT2A (0.60) | SMN1; SMN2KDM4EKMT2AMEN1L3MBTL1 | |
| SCHEMBL158053 | 0.81 | SMN1; SMN2 (0.67) | SMN1; SMN2KDM4EKMT2AMEN1L3MBTL1 | |
| SCHEMBL306514 | 0.81 | SMN1; SMN2 (0.67) | SMN1; SMN2KDM4EKMT2AMEN1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1082291-B1 | CHEMICAL PROCESS FOR THE STEREOSELECTIVE SYNTHESIS OF R-(-)-CARNITINE | SIGMA TAU IND FARMACEUTI (IT) | 2004-09-08 | — | — | EP | disclosed |
| US-6420599-B2 | CHARACTERIZING STEP IS THE CONDENSATION OF GLYCEROL WITH (-)CAMPHORSULFONAMIDE | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2002-07-16 | — | — | US | disclosed |
| US-20010003135-A1 | Chemical process for the stereoselective synthesis of R-(-)- carnitine | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2001-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010003135-A1 | Chemical process for the stereoselective synthesis of R-(-)- carnitine | CRAT, COASY, CPT1B | SMN1; SMN2 2923/4885KDM4E 3735/4885KMT2A 3280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.